{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:38:54Z","timestamp":1775151534657,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/olq.0b013e318162c4d8","type":"journal-article","created":{"date-parts":[[2008,3,19]],"date-time":"2008-03-19T07:02:32Z","timestamp":1205910152000},"page":"414-419","source":"Crossref","is-referenced-by-count":44,"title":["A Randomized Six-Day Safety Study of an Antiretroviral Microbicide Candidate UC781, a Non-Nucleoside Reverse Transcriptase Inhibitor"],"prefix":"10.1097","volume":"35","author":[{"given":"Jill L.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kovalevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaim-Jou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Ballagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Douville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine K.","family":"Mauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne M.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210213","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1128\/AAC.40.6.1454","article-title":"Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at potency similar to that for wild-type virus.","volume":"40","author":"Balzarini","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20-20210213","doi-asserted-by":"crossref","first-page":"7786","DOI":"10.1021\/bi970140u","article-title":"The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.","volume":"36","author":"Barnard","year":"1997","journal-title":"Biochemistry"},{"key":"R3-20-20210213","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1128\/JVI.71.4.3023-3030.1997","article-title":"Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.","volume":"71","author":"Borkow","year":"1997","journal-title":"J Virol"},{"key":"R4-20-20210213","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/AAC.41.4.831","article-title":"Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.","volume":"41","author":"Buckheit","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20-20210213","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.43.2.259","article-title":"The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3\u2032-azido-3\u2032-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.","volume":"43","author":"Borkow","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20-20210213","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/JVI.80.9.4440-4446.2006","article-title":"In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.","volume":"80","author":"Hossain","year":"2006","journal-title":"J Virol"},{"key":"R7-20-20210213","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.48.1.337-339.2004","article-title":"In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC\u2013781 and TMC120-R147681 as human immunodeficiency virus microbicides.","volume":"48","author":"Van Herrewege","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20-20210213","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00002030-200303280-00002","article-title":"Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.","volume":"17","author":"Zussman","year":"2003","journal-title":"AIDS"},{"key":"R9-20-20210213","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.1128\/JVI.79.17.11179-11186.2005","article-title":"The nonnucleoside reverse transcriptase inhibitor UC781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.","volume":"79","author":"Fletcher","year":"2005","journal-title":"J Virol"},{"key":"R10-20-20210213","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/AAC.48.10.3834-3844.2004","article-title":"In vitro comparison of topical microbicides for prevention of human deficiency virus type 1 transmission.","volume":"48","author":"Dezzutti","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20-20210213","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/AAC.01129-06","article-title":"Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.","volume":"51","author":"Cummins","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20-20210213","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/aid.2005.21.845","article-title":"In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.","volume":"21","author":"Tien","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R13-20-20210213","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.contraception.2006.09.003","article-title":"Fourteen day safety and acceptability study of the universal placebo gel: A randomized double blind phase I safety study.","volume":"75","author":"Schwartz","year":"2007","journal-title":"Contraception"},{"key":"R14-20-20210213","article-title":"World Health Organization and CONRAD Manual for the standardization of colposcopy for the evaluation of vaginally administered products, Update 2000","year":"2000"},{"key":"R15-20-20210213","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.aids.0000210608.70762.c3","article-title":"Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.","volume":"20","author":"Mayer","year":"2006","journal-title":"AIDS"},{"key":"R16-20-20210213","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/sti.76.2.126","article-title":"A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.","volume":"76","author":"Van Damme","year":"2000","journal-title":"Sex Transm Infect"},{"key":"R17-20-20210213","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1086\/314881","article-title":"The effects of three nonoxynol-9 preparations on vaginal flora and epithelium.","volume":"180","author":"Watts","year":"1999","journal-title":"J Infect Dis"},{"key":"R18-20-20210213","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(02)11079-8","article-title":"Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial.","volume":"360","author":"Van Damme","year":"2002","journal-title":"Lancet"},{"key":"R19-20-20210213","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/sti.76.6.480","article-title":"Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide.","volume":"76","author":"Coggins","year":"2000","journal-title":"Sex Transm Infect"}],"container-title":["Sexually Transmitted Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007435-200804000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:35:01Z","timestamp":1618036501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007435-200804000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/olq.0b013e318162c4d8","relation":{},"ISSN":["0148-5717"],"issn-type":[{"value":"0148-5717","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}